Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Are Ultragenyx, REGENXBIO In A Bidding War For Dimension?

Executive Summary

ProQR spinout Amylon gets started by licensing four central nervous system disorder candidates from its parent, while start-up Eyevance gets US rights to Nicox’s Zerviate.

Advertisement

Related Content

SpringWorks Launches With $103m, Four Pfizer Drugs And A Focus On Underserved Patients
Nuvelution Puts Business Model Into Action With Teva/Austedo Deal
Deal-Making Firm On Fosun’s Agenda As Overseas Revenues Spurt
Teva Offloads Women's Health Business To Two Firms For $1.38Bn
Fosun Tweaks Gland Deal Amid Limbo In India
What's Driving The Uptick In Korea-China Biotech Deals
Keeping Track: Oncology Announcements, Priority Review Vouchers Continue To Pile Up
Onxeo Seeks Partner For Its Expanding Oncology Pipeline
Onxeo Buys DNA Repair Technology; Delays PhIII For Validive
Over-ambitious ThromboGenics 'explores options' after poor US Jetrea launch

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099559

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel